The 13 most recent market catalysts affecting $STAA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
STAAR Surgical shares are trading higher after the company announced a $50 million share buyback program.
The share buyback program signals management's belief that STAAR Surgical's stock is undervalued, which often instills investor confidence and can lead to increased demand for the …
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
STAAR Surgical Announces New $50M Share Buyback Program
STAAR Surgical's $50M share buyback program is a positive corporate catalyst, indicating management's belief that the stock is undervalued and a commitment to returning capital to …
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 65
Staar Surgical shares are trading lower after Stifel lowered its price target on the stock from $31 to $28.
The lowering of a price target by a reputable firm like Stifel directly impacts investor sentiment and can trigger selling pressure, as seen with Staar Surgical. This action sugges…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 55
Stifel Maintains Hold on Staar Surgical, Lowers Price Target to $28
Stifel analyst Thomas Stephan maintained a 'Hold' rating on Staar Surgical (STAA) but lowered the price target from $31 to $28. This action indicates a slightly less optimistic val…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Sell on Staar Surgical, Lowers Price Target to $19
UBS analyst Patrick Wood maintained a 'Sell' rating on Staar Surgical and lowered the price target from $20 to $19. This action indicates a continued negative outlook from a promin…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Outperform on Staar Surgical, Lowers Price Target to $37
Wedbush analyst Michael Piccolo maintained an 'Outperform' rating on Staar Surgical (STAA) but lowered the price target from $40 to $37. This action signals a slight recalibration …
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 92
Staar Surgical Q2 EPS $0.16 Beats $0.15 Estimate, Sales $93.535M Beat $90.589M Estimate
Staar Surgical reported Q2 EPS of $0.16, beating the $0.15 estimate by 6.67%, and sales of $93.535 million, surpassing the $90.589 million estimate by 3.25%. This represents a subs…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Reiterates Outperform on Staar Surgical, Maintains $40 Price Target
Wedbush analyst Michael Piccolo has reaffirmed an 'Outperform' rating and a $40 price target for Staar Surgical (STAA). This action signals that the analyst's investment thesis for…
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 85
STAAR Surgical shares are trading lower. The company reported Q2 preliminary results.
This headline represents a significant corporate catalyst for STAAR Surgical. Preliminary results often set the tone for the full earnings report, and a negative reaction suggests …
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions
STAAR Surgical's preliminary Q2 results show robust overall growth, primarily due to the normalization of operations and inventory levels in China, and strong performance in the Am…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 75
STAAR Surgical shares are trading lower. The company reported Q2 preliminary results.
The headline signals a corporate catalyst, specifically a negative earnings pre-announcement or preliminary results that disappointed investors. This directly impacts STAAR Surgica…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
STAAR Surgical Reports Q2 Preliminary Net Sales To Be Over $90M
STAAR Surgical reported preliminary Q2 2026 net sales exceeding $90 million, more than doubling the $44.3 million from Q2 2025. This significant growth indicates robust demand for …
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Reiterates Outperform on Staar Surgical, Maintains $40 Price Target
Wedbush analyst Michael Piccolo reiterated an 'Outperform' rating and maintained a $40 price target for Staar Surgical (STAA). This action signals that the analyst's view on the co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.